Overall, our results indicate that administering UT to obese mice induced an improvement in the anti-inflammatory state of the liver and may be considered a potential therapeutic intervention for enhancing hepatic insulin sensitivity and in the reversion of NASH to a less harmful NAFLD. The gene discussed is INS; the disease is metabolic dysfunction-associated steatohepatitis.